Triple-negative versus non-triple-negative breast cancers in high-risk women: Phenotype features and survival from the HIBCRIT-1 MRI-including screening study

Clinical Cancer Research

Volumn 22, Issue 4, 2016, Pages 895-904

  Podo, Franca ^a   Santoro, Filippo ^a   Di Leo, Giovanni ^b   Manoukian, Siranoush ^c   De Giacomi, Clelia ^d   Corcione, Stefano ^e   Cortesi, Laura ^f   Carbonaro, Luca A ^b   Trimboli, Rubina M ^b   Cilotti, Anna ^g   Preda, Lorenzo ^h   Bonanni, Bernardo ^h   Pensabene, Matilde ⁱ   Martincich, Laura ^j   Savarese, Antonella ^k   Contegiacomo, Alma ⁱ   Sardanelli, Francesco ^b,l  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e Sant'Anna Universitary Hospital   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁱ FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^j CANDIOLO CANCER INSTITUTE   (Italy)

^k REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; DATA ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; ECHOMAMMOGRAPHY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MEDICAL HISTORY; MENOPAUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; AGED; CARCINOMA, DUCTAL, BREAST; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; RISK; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; CARCINOMA, DUCTAL, BREAST; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; MUTATION; PHENOTYPE; RISK; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84964253698     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0459     Document Type: Article

References (46)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature 2000;406:747-52.
2. Lakhani SR, Van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffoq L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2 and p53 in patients with BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
3. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, et al. The prognostic implication of the basal-like (cycle E high/p27low/ p53+/glomeruloid-microvascular proliferation+) phenotype of BRCA1- related breast cancer. Cancer Res 2004;64:830-5.
4. Reis-Filho JS, Tutt AN. Triple negative tumors: a critical review. Histopathology 2008;52:108-18.
5. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
6. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, et al. Triple-negative breast cancer: present challenges and new perspectives [review]. Mol Oncol 2010;4:209-29.
7. Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research [review]. Cancer Treat Rev 2010;36:206-15.
8. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
9. Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, et al. The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and progressive markers. J Thorac Dis 2014;6:1329-35.
10. Domingo L, Salas D, Zubizarreta R, Baré M, Sarriugarte G, Barata T, et al. INCA Study Group. Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Res 2014;16:R3.
11. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
12. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from International Breast Cancer Study Group Trials VIII and IX. J Clin Oncol 2013;31:3083-90.
13. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76.
14. Tun NM, Villani G, Ong K, Yoe L, Bo ZM. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta analysis. Clin Genet 2014;85:43-8.
15. Brekelmans CT, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus- Linthorst MM, Bartels CC, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006;17:391-400.
16. Møller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, et al. Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int J Cancer 2007;121:1017-20.
17. Sardanelli F, Podo F, D'Agnolo G, Verdecchia A, Santaquilani M, Musumeci R, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007;242:698-715.
18. Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the High Breast Cancer Risk Italian 1 study). Final results. Invest Radiol 2011;46:94-105.
19. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-25.
20. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:8469-76.
21. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78.
22. Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007;16:367-74.
23. Riedl CC, Ponhold L, Floíry D, WeberM, Kroiss R, Wagner T, et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res 2007;13:6144-52.
24. Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, et al. BRCA1-associated breast cancers present differently from BRCA2- associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010;28:5265-73.
25. Kuhl CK, Weigel S, Schrading S, Arande B, Bieling H, König R, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010;28:1450-7.
26. American College of Radiology (ACR). Breast imaging reporting and data system (BI-RADS) Atlas. 4th ed. Reston, VA: American College of Radiology; 2003.
27. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
28. Bauer KR, Beown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007;109:1721-8.
29. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109: 25-32.
30. Chen J-H, Agrawal G, Feig B, Baek H-M, Carpenter PM, Mehta RS, et al. Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol 2007;18:2042-3.
31. Cleator S, HellerW, Coombes RC. Triple-negative breast cancer: therapeutic options [review]. Lancet Oncol 2007;8:235-44.
32. Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, et al. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res 2014;16:435.
33. Dent R, Warner E. Screening for hereditary breast cancer. Semin Oncol 2007;34:392-400.
34. Santoro F, Podo F, Sardanelli F. Screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis. Breast Cancer Res Treat 2014;147:685-7.
35. Møller P, Stormorken A, Jonsrud C, HolmenMM, Hagen AI, Clark N, et al. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Res Treat 2013;139: 155-61.
36. Evans DG, Kesavan N, Lim Y, Gadde S, Hurley E, Massat NJ, et al.MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 2014;145:663-72.
37. Schrading S, Kuhl CK. Mammographic, US, andMRimaging phenotypes of familial breast cancer. Radiology 2008;246:58-70.
38. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009;250: 638-47.
39. Youk JH, Son EJ, Chung J, Kim J-A, Kim EK. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. Eur Radiol 2012; 22:1724-34.
40. Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 2003;98:1569-77.
41. Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer 2015;136:668-77.
42. Tharmaratnam K, Hagen AI, Møller P. MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis. Breast Cancer Res Treat 2014;148:687-8.
43. Evans DG. BCRT response to Møller. Breast Cancer Res Treat 2014;148:693.
44. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000;11:307-13.
45. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004;6:R8-R17.
46. Evans DG, Howell A. Are BRCA1- and BRCA2-related breast cancers associated with increased mortality? Breast Cancer Res 2004;6:E7.